Earnings Call Summary | Biodesix(BDSX.US) Q2 2024 Earnings Conference
Earnings Call Summary | Biodesix(BDSX.US) Q2 2024 Earnings Conference
Gross margin was consistently strong at 78.4%.The following is a summary of the Biodesix, Inc. (BDSX) Q2 2024 Earnings Call Transcript:
以下是Biodesix，Inc.（BDSX）2024年Q2業績會議電話交流紀要：
Financial Performance:
金融業績：
Total Q2 2024 revenue was $17.9 million, a 51% increase year-over-year, with lung diagnostic tests contributing $16.5 million.
Adjusted EBITDA improved by 38% year-over-year.
Gross margin was consistently strong at 78.4%.
2024年Q2總營業收入爲1790萬美元，同比增長51％，其中肺部診斷測試貢獻了1650萬美元。
調整後的息稅折舊及攤銷前利潤同比增長38％。
毛利率保持穩定高達78.4％。
Business Progress:
業務進展：
Biodesix has seen a 42% growth in test volumes along with a significant increase in its sales team, aimed at broader market penetration for its diagnostics.
Added several new reimbursement coverage policies and contracts for Nodify XL2 for better revenue per test.
Published new data supporting the clinical utility of their tests and continued contracted but unrecognized revenue in their biopharma services.
Named to Inc Magazine's 2024 Best Workplaces, reflecting strong internal culture and commitment.
Biodesix看到了42％的測試量增長，並在銷售團隊方面大幅增加，旨在更廣泛地滲透其診斷市場。
爲Nodify XL2添加了幾個新的償付報銷政策和合同，以獲得更好的每次測試收益。
發佈了支持其測試臨床實用性的新數據，並繼續在其生物製藥服務業務中存在但未被認可的收入合同。
被《Inc Magazine》評爲2024年最佳工作場所，反映了強大的內部文化和承諾。
Opportunities:
機會：
Biodesix raised its 2024 total revenue guidance to $70 million to $72 million, reflecting confidence in continued growth and market penetration.
Expanding lung diagnostic sales force to increase market reach.
Positive traction in securing more private payer coverage policies for tests.
Biodesix將2024年總營收指導提高到7000萬至7200萬美元，反映了對持續增長和市場滲透的信懇智能。
擴大肺部診斷銷售團隊以增加市場覆蓋範圍。
在爲測試獲得更多私人支付者覆蓋政策方面表現出積極的進展。
Risks:
風險：
Operational expansions require prudent investment, particularly in the Kansas laboratory for future capabilities of Nodify test development and other operations.
運營擴展需要謹慎投資，特別是在Kansas實驗室方面，以便未來提高Nodify測試開發和其他運營能力。
More details: Biodesix IR
更多細節：Biodesix IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。
